

**Germany CAR-T Cell Therapy Market Segmented Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others), By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others), By Treatment Type (Single Treatment, Combination Treatment), By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others) Region and Competition, Opportunity, and Forecast, 2018-2028**

<https://marketpublishers.com/r/G3C667C86E88EN.html>

Date: November 2023

Pages: 81

Price: US\$ 3,500.00 (Single User License)

ID: G3C667C86E88EN

## **Abstracts**

Germany CAR-T Cell Therapy Market is anticipated to project robust growth in the forecast period. The CAR-T cell therapy market in Germany has been gaining significant momentum and attention in recent years, reflecting the country's prominent position in the field of healthcare and biotechnology. CAR-T cell therapy, or Chimeric Antigen Receptor T-cell therapy, represents a groundbreaking approach in the

treatment of various cancers, offering new hope to patients with refractory or relapsed malignancies.

Germany has established itself as a key player in the global CAR-T cell therapy market, owing to its robust healthcare infrastructure, world-class research institutions, and a thriving pharmaceutical and biotechnology industry. The country's emphasis on innovation and clinical excellence has propelled it to the forefront of this cutting-edge therapy.

German pharmaceutical companies, in collaboration with research organizations, have been actively involved in the development and commercialization of CAR-T cell therapies. These therapies are designed to reprogram a patient's own T-cells to target and destroy cancer cells, offering a promising alternative to traditional cancer treatments.

One of the notable collaborations in the German CAR-T cell therapy market is between biopharmaceutical companies and academic institutions. This collaboration has led to advancements in treatment options for hematological malignancies, such as leukemia and lymphoma. Furthermore, CAR-T cell therapies are being explored for their potential in treating solid tumors, expanding the range of applications for this innovative technology.

Germany's regulatory framework and healthcare system have been supportive of CAR-T cell therapy adoption. The country has witnessed the approval of several CAR-T therapies for use in clinical settings, offering patients access to these cutting-edge treatments.

## Key Market Drivers

### Growing Pharmaceutical and Biotechnology Industry

The remarkable growth of the pharmaceutical and biotechnology industry in Germany is playing a pivotal role in propelling the CAR-T cell therapy market to new heights. These industries have been at the forefront of the development, commercialization, and expansion of innovative therapies like CAR-T cell treatments, bringing fresh hope to patients with challenging-to-treat malignancies.

Germany's pharmaceutical and biotechnology sectors have established themselves as leaders in research, development, and production, and their continued investment in

CAR-T cell therapy is driving the market forward. Leading pharmaceutical companies, in collaboration with academic institutions and smaller biotech firms, have channeled substantial resources and expertise into advancing CAR-T therapies. This synergy has not only expedited the clinical development of these groundbreaking treatments but also ensured a robust supply chain for CAR-T therapies, addressing the logistics and manufacturing aspects.

Moreover, the pharmaceutical and biotechnology industry's focus on cutting-edge research and development has led to an expansion of applications for CAR-T cell therapies. Initially designed for hematological malignancies, CAR-T therapies are now showing promise in treating solid tumors. This broadening scope opens up new market opportunities and encourages further investment in research, clinical trials, and therapeutic applications.

The success of CAR-T cell therapies in clinical settings has further fueled the commitment of the pharmaceutical and biotechnology sector to the CAR-T cell therapy market. Patients with limited or no alternative treatment options have experienced impressive remissions and improved quality of life. Such positive outcomes not only generate demand from patients and healthcare providers but also attract significant investment in CAR-T research and development.

### Robust Healthcare Infrastructure

Germany's CAR-T cell therapy market has experienced significant growth, largely propelled by the country's robust healthcare infrastructure. The nation's healthcare system is renowned for its accessibility, quality, and efficient delivery of medical services, making it an ideal environment for the development, application, and success of cutting-edge therapies like CAR-T cell treatments.

One key factor contributing to the growth of the CAR-T cell therapy market is the extensive network of well-equipped hospitals, clinics, and research facilities in Germany. This infrastructure ensures that CAR-T therapies can be effectively administered, monitored, and scaled up. Moreover, the presence of top-tier medical professionals and researchers in the country facilitates the seamless integration of CAR-T therapy into clinical practice.

Germany's healthcare system also provides a supportive framework for conducting clinical trials and research. This regulatory environment promotes innovation and encourages the development of CAR-T cell therapies by streamlining approval

processes and providing a clear pathway for research and development. These factors are crucial for expediting the clinical implementation of CAR-T treatments.

Furthermore, the efficiency and accessibility of healthcare services in Germany have been instrumental in the rapid adoption of CAR-T cell therapy. Patients have quicker access to advanced treatments, and healthcare providers can efficiently deliver these therapies to those in need. This contributes to improved patient outcomes and enhanced safety, which, in turn, bolster the reputation and acceptance of CAR-T cell therapy in the country.

### Rise in Research and Academic Excellence

The surge in research and academic excellence in Germany is a driving force behind the remarkable growth of the CAR-T cell therapy market in the country. Germany has long been recognized for its exceptional research institutions, academic prowess, and a strong tradition of scientific rigor. This research and academic excellence has been instrumental in propelling CAR-T cell therapy to the forefront of innovative cancer treatments.

Collaborations between renowned universities, research centers, and the biopharmaceutical industry have paved the way for groundbreaking developments in CAR-T cell therapy. These partnerships facilitate the seamless transition from research to clinical application, accelerating the adoption of CAR-T treatments. Multidisciplinary collaborations enable the sharing of knowledge, resources, and expertise, creating an environment conducive to the rapid advancement of CAR-T therapies.

One of the key drivers of CAR-T therapy in Germany is the success of clinical trials and research initiatives. Academic institutions and research organizations have been at the forefront of pioneering CAR-T therapy, leading to positive outcomes and groundbreaking discoveries. As CAR-T treatments consistently demonstrate their potential to offer long-lasting remissions for patients with refractory cancers, it fuels interest from both researchers and the industry, driving further investments and research efforts.

Moreover, the expansion of applications for CAR-T cell therapies, from hematological malignancies to solid tumors, is a direct result of the relentless pursuit of excellence in German academic and research institutions. These developments open up new market opportunities and attract substantial investment in research, clinical trials, and therapeutic applications, thereby expanding the reach and impact of CAR-T therapies.

## Key Market Challenges

### High Development Costs

The CAR-T cell therapy market in Germany holds immense potential for transforming cancer treatment. These innovative therapies, known for their remarkable success in certain malignancies, have opened new avenues for addressing previously untreatable conditions. However, a significant challenge that hinders the market's growth is the high development costs associated with CAR-T cell therapy.

The process of developing a CAR-T cell therapy from concept to commercialization is a complex and resource-intensive journey. It involves multiple stages, including preclinical research, clinical trials, manufacturing, and regulatory approvals. Conducting clinical trials, an essential step to evaluate the safety and efficacy of CAR-T cell therapies, is a major expense. These trials require a substantial patient pool, specialized infrastructure, and rigorous monitoring to ensure patient safety.

The regulatory processes associated with CAR-T cell therapies are stringent, necessitating comprehensive data collection and analysis. Ensuring compliance with these requirements can lead to additional costs. The manufacturing of CAR-T cell therapies is highly specialized and necessitates state-of-the-art facilities. Ensuring quality and consistency in the production process is paramount but comes at a significant financial cost.

CAR-T cell therapy development entails extensive research and development efforts, including preclinical studies to determine the therapy's feasibility and effectiveness. These phases are time-consuming and resource intensive.

### Complex Manufacturing Processes

CAR-T cell therapies are personalized for each patient, involving the extraction of a patient's T-cells, their genetic modification, and the expansion of these cells in the lab. This personalized approach is one of the hallmarks of CAR-T therapy but also contributes to its complexity, making it time-consuming and resource-intensive.

Ensuring consistent and high-quality manufacturing of CAR-T therapies is paramount for patient safety and treatment effectiveness. Variability in the manufacturing process can result in unpredictable patient outcomes, necessitating stringent quality control

measures, which add to the complexity.

The manufacturing of CAR-T cell therapies requires specialized facilities with stringent environmental controls to prevent contamination and maintain the integrity of the cellular products. These specialized facilities are costly to establish and maintain.

To operate these specialized facilities and ensure the proper handling of patient cells, a highly skilled workforce is essential. Recruitment, training, and retention of these personnel can be challenging.

Each patient's T-cells are unique, and the manufacturing process must be tailored to individual genetic profiles. This personalized approach, while a strength of CAR-T therapy, presents a complex logistical challenge.

## Key Market Trends

### Expanding Applications

Expanding applications represent a pivotal trend that is propelling the Germany CAR-T cell therapy market to new heights. Originally developed to target hematological malignancies, such as leukemia and lymphoma, CAR-T cell therapies have seen their applications broaden significantly. This trend is driven by innovative research and clinical trials aimed at harnessing the potential of CAR-T technology in treating various types of solid tumors.

The expansion of applications for CAR-T cell therapies is a game-changer for the German market. As clinical trials and research progress, more cancer types are becoming eligible for CAR-T treatments. This means that a broader spectrum of patients, including those with refractory or relapsed solid tumors, can now benefit from these innovative therapies. This increased scope enhances the market's potential reach and impact on patients' lives.

Furthermore, the emergence of CAR-T therapies for solid tumors is redefining the paradigm of cancer treatment. Historically, many solid tumors have been notoriously difficult to address effectively. The innovative approach of CAR-T cell therapies in targeting specific cancer antigens offers new hope to patients facing these challenging malignancies. As a result, the growing interest and investment in applying CAR-T technology to solid tumors have made Germany a significant hub for research and clinical trials in this domain.



This trend is not only expanding the portfolio of CAR-T cell therapies but also contributing to the market's growth and attracting greater interest from both pharmaceutical companies and healthcare providers. As the research into CAR-T cell therapy continues to evolve, patients in Germany and around the world stand to benefit from a broader range of treatment options and improved outcomes in the fight against cancer.

### Clinical Trial Advancements

Clinical trial advancements represent a significant driver behind the growth of the CAR-T cell therapy market in Germany. These trials serve as a pivotal bridge between research and real-world patient care, allowing innovative therapies to prove their safety and efficacy. In the case of CAR-T cell therapy, clinical trials have played a transformative role in advancing this cutting-edge technology.

Germany is known for its commitment to clinical research and medical innovation, and this has been particularly evident in the field of CAR-T cell therapy. Clinical trials in Germany have served as vital platforms for evaluating the safety, effectiveness, and potential applications of CAR-T therapies. These trials have provided essential insights into patient outcomes, treatment protocols, and any potential side effects, enabling researchers and healthcare providers to refine and optimize CAR-T treatments.

Moreover, clinical trials in Germany have led to significant breakthroughs in expanding the applications of CAR-T cell therapy. While CAR-T treatments were initially developed for hematological malignancies, such as leukemia and lymphoma, advancements in clinical research have facilitated the exploration of CAR-T therapies in addressing solid tumors. This expansion of applications has not only broadened the scope of CAR-T therapy but also increased the market's reach and potential patient population.

Furthermore, clinical trial data have bolstered confidence among healthcare providers and regulatory authorities. The success of CAR-T therapies in clinical trials has led to regulatory approvals and recommendations for the use of these treatments, ultimately driving their adoption in clinical practice. Patients who have participated in these trials have often experienced remarkable remissions and improved quality of life, further solidifying the value of CAR-T cell therapy.

### Segmental Insights

## Tumor Type Insights

Based on the Tumor Type, Hematological Malignancies emerged as the dominant segment in the Germany CAR-T Cell Therapy Market in 2022. CAR-T cell therapies have demonstrated remarkable success in treating hematological malignancies. Patients who have undergone CAR-T therapy have experienced significant remissions and, in some cases, long-term disease-free survival. This clinical success has created a strong demand for these innovative therapies among patients and healthcare providers.

Germany, like many developed nations, has a relatively high incidence of hematological malignancies. The prevalence of these cancers necessitates advanced and effective treatment options to address the growing patient population. Hematological malignancies can be particularly aggressive and difficult to treat using traditional methods such as chemotherapy and radiation therapy. CAR-T cell therapy offers a promising alternative, especially for patients who have not responded to or have relapsed after standard treatments.

## Indication Insights

Based on the indication, the Diffused Large B-cell Lymphoma (DLBCL) segment emerged as the dominant player in the Germany CAR-T Cell Therapy Market in 2022. DLBCL is the most common type of non-Hodgkin lymphoma, and its incidence rates have been rising in Germany and worldwide. This increased prevalence has created a substantial patient population in need of effective treatment options. DLBCL is known for its aggressive nature and resistance to traditional therapies like chemotherapy and radiation. As a result, patients often require innovative and more targeted treatment strategies like CAR-T cell therapy.

CAR-T cell therapy has demonstrated remarkable clinical success in treating DLBCL. Many patients who have received CAR-T treatments have experienced substantial remissions and improved quality of life, particularly when other treatments have failed.

## Regional Insights

Western region emerged as the dominant player in the Germany CAR-T Cell Therapy Market in 2022, holding the largest market share. Western Germany is the most densely populated region in the country. A higher population density often leads to a larger pool of patients, creating increased demand for innovative medical treatments like CAR-T therapy.



The Western region boasts state-of-the-art healthcare facilities, world-class hospitals, and renowned medical institutions. These institutions are more likely to adopt and offer advanced treatments, making CAR-T cell therapy more accessible to patients. Western Germany is economically prosperous, with a strong industrial and financial base. This prosperity often leads to greater investment in healthcare, research, and technology, facilitating the adoption of cutting-edge therapies like CAR-T.

### Key Market Players

Gilead Sciences, Inc

Novartis International AG

Bristol Myers Squibb Co.

AbbVie Inc.

Cellectis SA

Amgen Inc

Pfizer Inc.

Merck & Co. Inc.

Intellia Therapeutics Inc.

Poseida Therapeutics Inc

### Report Scope:

In this report, the Germany CAR-T Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

#### Germany CAR-T Cell Therapy Market, By Product Type:

Yescarta

Kymriah

Tecartus

Breyanzi

Abecma

Others

Germany CAR-T Cell Therapy Market, By Tumor Type:

Hematological Malignancies

Solid Tumors

Germany CAR-T Cell Therapy Market, By Indication:

Diffused Large B-Cell Lymphoma (DLBCL)

Acute Lymphoblastic Leukemia (ALL)

Follicular Lymphoma (FL)

Mantle Cell Lymphoma (MCL)

Others

Germany CAR-T Cell Therapy Market, By Treatment Type:

Single Treatment

Combination Treatment

Germany CAR-T Cell Therapy Market, By Targeted Antigen:

CD 19

BCMA (B-Cell Maturation Antigen)

Others

Germany CAR-T Cell Therapy Market, By End User:

Hospitals

Specialty Clinics

Ambulatory Surgical Centers

Others

Germany CAR-T Cell Therapy Market, By Region:

Eastern

Central

Western

Rest of Germany

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Germany CAR-T Cell Therapy Market.

Available Customizations:

Germany CAR-T Cell Therapy Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

*Germany CAR-T Cell Therapy Market Segmented Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagen...)*



## Contents

### 1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### 2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### 3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

### 4. GERMANY CAR-T CELL THERAPY MARKET OUTLOOK

- 4.1. Market Size & Forecast
  - 4.1.1. By Value
- 4.2. Market Share & Forecast
  - 4.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others)
  - 4.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
  - 4.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)

- 4.2.4. By Treatment Type (Single Treatment, Combination Treatment)
- 4.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)
- 4.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
- 4.2.7. By Company (2022)
- 4.2.8. By Region

#### 4.3. Market Map

- 4.3.1. By Product Type
- 4.3.2. By Tumor Type
- 4.3.3. By Treatment Type
- 4.3.4. By Targeted Antigen
- 4.3.5. By End User
- 4.3.6. By Region

### 5. WESTERN GERMANY CAR-T CELL THERAPY MARKET OUTLOOK

#### 5.1. Market Size & Forecast

- 5.1.1. By Value

#### 5.2. Market Share & Forecast

- 5.2.1. By Product Type
- 5.2.2. By Tumor Type
- 5.2.3. By Treatment Type
- 5.2.4. By Targeted Antigen
- 5.2.5. By End User

### 6. CENTRAL GERMANY CAR-T CELL THERAPY MARKET OUTLOOK

#### 6.1. Market Size & Forecast

- 6.1.1. By Value

#### 6.2. Market Share & Forecast

- 6.2.1. By Product Type
- 6.2.2. By Tumor Type
- 6.2.3. By Treatment Type
- 6.2.4. By Targeted Antigen
- 6.2.5. By End User

### 7. EASTERN GERMANY CAR-T CELL THERAPY MARKET OUTLOOK

#### 7.1. Market Size & Forecast

- 7.1.1. By Value



## 7.2. Market Share & Forecast

7.2.1. By Product Type

7.2.2. By Tumor Type

7.2.3. By Treatment Type

7.2.4. By Targeted Antigen

7.2.5. By End User

## 8. REST OF GERMANY CAR-T CELL THERAPY MARKET OUTLOOK

### 8.1. Market Size & Forecast

8.1.1. By Value

### 8.2. Market Share & Forecast

8.2.1. By Product Type

8.2.2. By Tumor Type

8.2.3. By Treatment Type

8.2.4. By Targeted Antigen

8.2.5. By End User

## 9. MARKET DYNAMICS

9.1. Drivers

9.2. Challenges

## 10. MARKET TRENDS & DEVELOPMENTS

10.1. Recent Developments

10.2. Product Launches

10.3. Mergers & Acquisitions

## 11. GERMANY CAR-T CELL THERAPY MARKET: SWOT ANALYSIS

## 12. PORTER'S FIVE FORCES ANALYSIS

12.1. Competition in the Industry

12.2. Potential of New Entrants

12.3. Power of Suppliers

12.4. Power of Customers

12.5. Threat of Substitute Product

## **13. COMPETITIVE LANDSCAPE**

### 13.1. Gilead Sciences, Inc

13.1.1. Business Overview

13.1.2. Company Snapshot

13.1.3. Products & Services

13.1.4. Current Capacity Analysis

13.1.5. Financials (In case of listed)

13.1.6. Recent Developments

13.1.7. SWOT Analysis

### 13.2. Novartis International AG

### 13.3. Bristol Myers Squibb Co.

### 13.4. AbbVie Inc.

### 13.5. Cellectis SA

### 13.6. Amgen Inc

### 13.7. Pfizer Inc.

### 13.8. Merck & Co. Inc.

### 13.9. Intellia Therapeutics Inc.

### 13.10. Poseida Therapeutics Inc

## **14. STRATEGIC RECOMMENDATIONS**

## **15. ABOUT US & DISCLAIMER**

## I would like to order

Product name: Germany CAR-T Cell Therapy Market Segmented Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others), By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others), By Treatment Type (Single Treatment, Combination Treatment), By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others) Region and Competition, Opportunity, and Forecast, 2018-2028

Product link: <https://marketpublishers.com/r/G3C667C86E88EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3C667C86E88EN.html>